Calcineurin A-β is required for hypertrophy but not matrix expansion in the diabetic kidney

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 414-422

  Reddy, Ramesh N ^a   Knotts, Taylor L ^a   Roberts, Brian R ^a   Molkentin, Jeffery D ^c   Price, S Russ ^a   Gooch, Jennifer L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Calcineurin; Cyclosporine; Diabetes; Renal hypertrophy

Indexed keywords

ALBUMINOID; CALCINEURIN; CYCLOSPORIN; GLUCOSE; MTOR PROTEIN, MOUSE; PROTEIN PHOSPHATASE 3, CATALYTIC SUBUNIT, BETA ISOFORM, MOUSE; STRESS ACTIVATED PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BIOSYNTHESIS; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HYPERTROPHY; KIDNEY; METABOLISM; MOUSE; MOUSE MUTANT; PANCREAS ISLET BETA CELL; PATHOLOGY; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL;

ALBUMINS; ANIMALS; BLOOD UREA NITROGEN; CALCINEURIN; CYCLOSPORINE; DIABETES MELLITUS, EXPERIMENTAL; EXTRACELLULAR MATRIX; GLOMERULAR FILTRATION RATE; GLUCOSE; HYPERTROPHY; INSULIN-SECRETING CELLS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KIDNEY; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

MAMMALIA; MUS;

EID: 79951893531     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00910.x     Document Type: Article

References (29)

1. Dunn S, Burns J, Michel R. Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem. 1999; 274: 21908-12.
2. Lim HW, De Windt LJ, Steinberg L, et al Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. 2000; 101: 2431-7.
3. Musaro A, McCullagh KJ, Naya FJ, et al IGF-I induces skeletal myocyte hypertrophy in association with GATA-2 and NF-ATc1. Nature. 1999; 400: 581-5.
4. +-dependent calcineurin signalling pathway. Nature. 1999; 400: 576-80.
5. Gooch JL, Tang Y, Ricono JM, et al Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-depend-ent mechanism. J Biol Chem. 2001; 276: 42492-500.
6. Gooch JL, Gorin Y, Zhang BX, et al Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation. J Biol Chem. 2004; 279: 15561-70.
7. Cobbs SL, Gooch JL. NFATc is required for TGFbeta-mediated transcriptional regulation of fibronectin. Biochem Biophys Res Commun. 2007; 362: 288-94.
8. Gooch JL, Barnes JL, Garcia S, et al Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation. Am J Physiol Renal Physiol. 2003; 284: F144-54.
9. Gooch JL, Toro JJ, Guler RL, et al Calcineurin A-alpha but not A-beta is required for normal kidney development and function. Am J Pathol. 2004; 165: 1755-65.
10. Bueno OF, Wilkins BJ, Tymitz KM, et al Calcineurin Abeta-deficient mice. Proc Natl Acad Sci. 2002; 99: 4586-91.
11. Wilkins BJ, Dai YS, Bueno OF, et al Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004; 94: 110-8.
12. Roberts B, Pohl J, Gooch JL. A fluorimet-ric method for determination of calcineurin activity. Cell Calcium. 2008; 43: 515-9.
13. Gooch JL, Pergola PE, Guler RL, et al Differential expression of calcineurin A isoforms in the diabetic kidney. J Am Soc Neph. 2004; 15: 1421-9.
14. Wolf G, Killen PD, Neilson EG. Cyclosporin A stimulates transcription and procollagen secretion in tubulointersititial fibroblasts and proximal tubule cells. J Am Soc Neph. 1990; 6: 918-22.
15. Rocco M, Chen Y, Goldfarb S, et al TGF-beta gene expression and bioactivity in proximal tubule. Kidney Intl. 1992; 41: 107-14.
16. Gooch JL, Roberts BR, Cobbs SL, et al Loss of the alpha isoform of calcineurin is sufficient to induce nephrotoxicity and altered expression of TGFbeta. Transplantation. 2007; 83: 439-47.
17. Sussman MA, Lim HW, Gude N, et al Prevention of cadiac hypertrophy in mice by calcineurin inhibition. Science. 1998; 281: 1690-3.
18. Murat A, Pellieux C, Brunner H-R, et al Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem. 2000; 275: 40867-73.
19. Molkentin J, Lu J, Antos C, et al A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215-28.
20. Bueno OF, Wilkins BJ, Tymitz KM, et al Impaired cardiac hypertrophic response in calcineurin Abeta-deficient mice. Proc Natl Acad Sci. 2002; 99: 4586-91.
21. Gooch JL. An emerging role for cal-cineurin Aalpha in the development and function of the kidney. Am J Physiol Renal Physiol. 2006; 290: F769-76.
22. Morancho B, Minguillon J, Molkentin JD, et al Analysis of the transcriptional activity of endogenous NFAT5 in primary cells using transgenic NFAT-luciferase reporter mice. BMC Mol Biol. 2008; 9: 13.
23. Takeishi Y, Ping P, Bolli R, et al Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res. 2000; 86: 1218-23.
24. Lim HW, De Windt LJ, MAnte J, et al Reversal of cardiac hypertrophy in transgenic disase models by calcineurin inhibition. J Mol Cell Cardio. 2000; 32: 697-709.
25. Goldspink P, McKinney R, Kimball V, et al Angiotensin induced cardiac hypertrophy in vivo is inhibited by cyclosporin in adult rats. Mol Cell Biochem. 2001; 226: 83-8.
26. DeWindt LJ, Lim HW, Bueno OF, et al Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci. 2001; 98: 3322-7.
27. Schiffer M, von Gersdorff G, Bitzer M, et al Smad proteins and transforming growth factor-beta signaling. Kidney Int Suppl. 2000; 77: S45-52.
28. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6: 729-34.
29. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124: 471-84.